Quick Answer
IRONWOOD PHARMACEUTICALS INC reported R&D Expense of $95.14 million for fiscal year 2025.
IRONWOOD PHARMACEUTICALS INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $95.14M | -14.6% |
| 2024 | $111.42M | -4.0% |
| 2023 | $116.08M | +162.3% |
| 2022 | $44.27M | -37.1% |
| 2021 | $70.41M | -20.1% |
| 2020 | $88.06M | -23.5% |
| 2019 | $115.04M | +13.8% |
| 2018 | $101.06M | +14.7% |
| 2017 | $88.14M | -36.8% |
| 2016 | $139.49M | +28.3% |
| 2015 | $108.75M | +6.7% |
| 2014 | $101.89M | -0.5% |
| 2013 | $102.38M | -9.8% |
| 2012 | $113.47M | +31.8% |
| 2011 | $86.09M | +11.2% |
| 2010 | $77.45M | +1.8% |
| 2009 | $76.10M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $22.47M | -24.7% | -3.9% |
| June 30, 2025 | $23.37M | -23.1% | -14.8% |
| March 31, 2025 | $27.43M | +6.3% | -8.0% |
| September 30, 2024 | $29.83M | -9.6% | -1.8% |
| June 30, 2024 | $30.39M | -12.1% | +17.7% |
| March 31, 2024 | $25.82M | +100.9% | -21.7% |
| September 30, 2023 | $32.98M | +185.7% | -4.6% |
| June 30, 2023 | $34.58M | +201.9% | +169.1% |
- IRONWOOD PHARMACEUTICALS INC showed a decrease of -14.6% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, IRONWOOD PHARMACEUTICALS INC’s r&d expense has grown by 25.0% (from $76.10 million to $95.14 million).
- The most recent figure is from IRONWOOD PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: